Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype

Journal of Pharmacology and Experimental Therapeutics

Volumn 313, Issue 1, 2005, Pages 302-309

  Lee, Su Jun ^a   Bell, Douglas A ^a   Coulter, Sherry J ^a   Ghanayem, Burhan ^a   Goldstein, Joyce A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GENOMIC DNA; NIFEDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450; DNA; RECOMBINANT PROTEIN;

ALLELE; AMINO ACID SEQUENCE; ARTICLE; CAUCASIAN; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME DEFECT; ETHNIC GROUP; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; METABOLIC RATE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REACTION TIME; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ALGORITHM; CHROMOSOME; GENETICS; ISOLATION AND PURIFICATION; KINETICS; METABOLISM; MOLECULAR GENETICS; OXIDATION REDUCTION REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM;

ALGORITHMS; ALLELES; AMINO ACID SEQUENCE; CALCIUM CHANNEL BLOCKERS; CHROMOSOMES; CYTOCHROME P-450 ENZYME SYSTEM; DNA; GENOTYPE; HAPLOTYPES; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; NIFEDIPINE; OXIDATION-REDUCTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECOMBINANT PROTEINS;

EID: 15744390776     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.078758     Document Type: Article

References (33)

1. Balram C, Zhou Q, Cheung YB, and Lee EJ (2003) CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol 59:123-126.
2. Barnes HJ, Arlotto MP, and Waterman MR (1991) Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proc Natl Acad Sci USA 88:5597-5601.
3. Chang FM, Kidd JR, Livak KJ, Pakstis AJ, and Kidd KK (1996) The world-wide distribution of allele frequencies at the human dopamine D4 receptor locus. Hum Genet 98:91-101.
4. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, and Goldstein JA (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299: 825-831.
5. Domanski TL, Liu J, Harlow GR, and Halpert JR (1998) Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation. Arch Biochem Biophys 350:223-232.
6. Evans WE and Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science (Wash DC) 286:487-491.
7. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, and Yamazoe Y (1997) Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 7:391-396.
8. Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, and Azuma J (2002) Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12:331-334.
9. Gibson GG, Plant NJ, Swales KE, Ayrton A, and El-Sankary W (2002) Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32:165-206.
10. Gillam EM, Guo Z, Ueng YF, Yamazaki H, Cock I, Reilly PE, Hooper WD, and Guengerich FP (1995) Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions and catalytic activities. Arch Biochem Biophys 317:374-384.
11. He YA, Roussel F, and Halpert JR (2003) Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. Arch Biochem Biophys 409:92-101.
12. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, and van Gelder T (2003) Genetic polymorphisms of the CYP3A4, CYP3A5 and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245-254.
13. Hodgson E (2003) In vitro human phase I metabolism of xenobiotics I: pesticides and related compounds used in agriculture and public health. J Biochem Mol Toxicol 17:201-206.
14. Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, and Huang JD (2001) Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 29:268-273.
15. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779.
16. King BP, Leathart JB, Mutch E, Williams FM, and Daly AK (2003) CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol 55:625-629.
17. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, et al. (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-1114.
18. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
19. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, Mohrenweiser HW, and Goldstein JA (2003) Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 13:461-472.
20. Li AP, Kaminski DL, and Rasmussen A (1995) Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1-8.
21. Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, and Watkins PB (1990) Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 335:11-15.
22. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification and properties. J Biol Chem 239:2379-2385.
23. Popova SN, Slominsky PA, Pocheshnova EA, Balanovskaya EV, Tarskaya LA, Bebyakova NA, Bets LV, Ivanov VP, Livshits LA, Khusnutdinova EK, et al. (2001) Polymorphism of trinucleotide repeats in loci DM, DRPLA and SCA1 in East European populations. Eur J Hum Genet 9:829-835.
24. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, and Gonzalez FJ (2000) CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48-56.
25. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
26. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, and Daly AK (2003) Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76:1233-1235.
27. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
28. Wacher VJ, Wu CY, and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
29. Wang H, Dick R, Yin H, Licad-Coles E, Kroetz DL, Szklarz G, Harlow G, Halpert JR, and Correia MA (1998) Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. Biochemistry 37:12536-12545.
30. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5 and CYP3A7. Drug Metab Dispos 30:883-891.
31. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, and Vandenbranden M (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38:207-213.
32. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution. J Biol Chem 279:38091-38094.
33. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, et al. (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3:477-483.